Study of two new medicines for people with a specific type of ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed ALS diagnosis by a neurologist.
- Your blood or spinal fluid must show a specific marker called GREM2, which is linked to certain ALS types.
- Your first ALS symptoms must have started within the last 2 years.
- Your functional abilities (using the ALSFRS-R scale) must be at least 25, and your breathing capacity must be at least 50% of normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.